Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. - Wikidata - awgldk - TriplyDB

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

http://www.wikidata.org/entity/Q34330678

about

The impact of environmental factors in severe psychiatric disorders.Brexpiprazole: so far so good D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review Inflammatory biomarkers as differential predictors of antidepressant response A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia 1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serine [Neurobiology of schizophrenia: new findings from the structure to the molecules].Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients Mechanism Underlying Acupuncture-Ameliorated Depressive Behaviors by Enhancing Glial Glutamate Transporter in Chronic Unpredictable Mild Stress (CUMS) Rats Propofol prevents electroconvulsive-shock-induced memory impairment through regulation of hippocampal synaptic plasticity in a rat model of depression Development of allosteric modulators of GPCRs for treatment of CNS disorders Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study.MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia.Differential Effects of D-Cycloserine and ACBC at NMDA Receptors in the Rat Entorhinal Cortex Are Related to Efficacy at the Co-Agonist Binding Site.Neuropsychological Impairment and Its Association with Violence Risk in Japanese Forensic Psychiatric Patients: A Case-Control Study GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688 Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants.Leading compounds for the validation of animal models of psychopathology.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.

P2860

Q21129355-1CB5C774-F468-4594-98BD-8AD409DA5973 Q26766401-123EAE03-8086-4EDA-B128-0A2C046847FD Q26781321-2B6B5652-9E74-493E-A2E9-C1C2D27505C3 Q26782982-34A9CE79-DB3C-48B6-8490-968C42C10D77 Q26782993-2B4E3518-B27A-44AE-8AC2-09EC97C067DE Q28081799-CAB8B527-B420-47C9-A3C0-E5BC61110A50 Q28082048-2B92BE84-A468-43C3-A53B-3FFAADF0E035 Q28083121-DAAFD6A1-8AD7-4125-9027-947817F8FCDE Q28266846-0A7CBAAA-0A5E-4021-8023-03AA995B71FA Q28277636-E03D4EE5-B69A-413E-BAE2-1FE04F793187 Q30363617-5430648A-7EA9-4B83-A632-E39479034C2E Q30371933-604A7AFF-694E-4D2C-B960-211200E04EFD Q30418172-D4346C90-4DF0-4068-BCE5-E975C1EBCC5C Q30455182-7A086E16-D354-4381-ABD8-FBF81B6C5E2C Q30842754-A4AC59E6-EF1C-4B3E-B8CE-8B745385B16C Q30848010-A854A76B-16A4-4B15-A9F6-5D625A5506CF Q31108616-65AA3425-95A8-4A8E-9259-60AA685680E8 Q33718794-C4282CC0-40EE-415F-A527-D42D527F2BD3 Q33858984-EEF4FD80-87C2-4A8D-A735-5D4D29C0769C Q34274590-BA04E594-0B86-4CED-AB83-9B72FFF504DC Q34373958-D34FBC5E-8023-4425-AB27-83D0AEFC8322 Q34492381-E27167E8-FB35-4477-ADE3-EB2B1FD07327 Q34513221-C34EA539-3422-49D4-BF0E-D88BBED304CF Q35071909-84D3018D-9309-488F-8025-A735FA28AAED Q35167939-9398BF43-E78B-4023-84E2-D80250FDF708 Q35598966-94F60A8D-C20C-4CEA-92CC-C1FC26A5B561 Q35699606-8A0334F1-2BD4-437F-BCF6-089CD1EEA88A Q35908405-7FDADE4A-A867-4F9A-B214-92DD890D6619 Q36486035-201981A7-65BA-4BA4-8628-6175A116329C Q36799359-DB9658B1-BB88-45A2-83D9-C4D0AD7AE6DC Q36915565-5122E9D2-5523-4991-811E-BFA9FB0F1E1E Q37054398-314D1879-50EB-439C-877E-5C84F679F83C Q37172873-043C0702-C54F-4E20-B254-ADDD8298B2AA Q37258840-C5ABC241-3A17-4AAC-82A1-758D8984F24F Q37310546-449D7BF1-E316-4A98-8AF9-5DE98C888B83 Q37347468-39F78FE0-2065-49F1-9C15-61EF74CA1F1D Q37662441-CCC04B38-B5FE-46B9-9FFD-61C4275D7F64 Q37668029-8AF723D5-D4CE-40FA-B32A-D0D154352683 Q38128733-03643B36-74FF-498F-A87D-2E1EC205CF09 Q38181363-D282FF95-50A0-4326-A9EA-7779477F3AD3

P2860

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

http://www.wikidata.org/entity/Q34330678

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Glutamate modulators as potent ...... renia and affective disorders.

@ast

Glutamate modulators as potent ...... renia and affective disorders.

@en

Glutamate modulators as potent ...... renia and affective disorders.

@nl

type

label

Glutamate modulators as potent ...... renia and affective disorders.

@ast

Glutamate modulators as potent ...... renia and affective disorders.

@en

Glutamate modulators as potent ...... renia and affective disorders.

@nl

prefLabel

Glutamate modulators as potent ...... renia and affective disorders.

@ast

Glutamate modulators as potent ...... renia and affective disorders.

@en

Glutamate modulators as potent ...... renia and affective disorders.

@nl

P1433

Q34330678-D3C735E4-9D6F-4398-A993-F53CB8BC11B8

P1476

Q34330678-35E1558E-5EE4-435B-BA25-54D047809916

P2093

Q34330678-C28FA5EA-CE0F-4432-9046-3363A3D4E6DF

P2860

Q34330678-01529698-9D7F-46D9-8E58-9131190BAD7A

Q34330678-02234057-D020-40E4-A8F6-5026CEAE5547

Q34330678-02B96998-9B20-4AF4-B7A6-B185672E7A80

Q34330678-04248F04-6D7F-423E-9AB7-0DEEE096609F

Q34330678-08C44AEF-6ED5-4E69-AB3D-77D11BCA887E

Q34330678-0956CDB8-307D-4D0C-81CC-C0C14E7F33AD

Q34330678-0E269F51-9911-482F-9895-975BE17B3736

Q34330678-0E2C6819-3CFE-4EC0-B675-51D009BDE9A4

Q34330678-0FF3D3CD-877D-402F-9992-3227AF537D78

Q34330678-103C3AA9-4D77-42AA-ACA1-E5F235ED7224

P2888

Q34330678-D56C3145-56C4-49AD-92B2-73B076BE0875

P304

Q34330678-230D616A-DCF6-4EC0-B0C7-4E246F55E257

P31

Q34330678-901D3A0E-573A-4A25-AAD4-FC7C3FBB7CAF

P356

Q34330678-60544BEE-A4D5-4EDA-87FB-9D9E4BD7192F

P433

Q34330678-271404CC-744F-4062-9DD1-75408EF6C267

P478

Q34330678-84498BB4-D2F3-4EF0-8EF5-6BA6E5595FE8

P50

Q34330678-1DF56079-3CC8-4D86-B5E1-E52F8574F6AF

Q34330678-2EC20C75-0B22-49C6-A924-BDEBCC00C00A

Q34330678-A69889AE-FCA6-4710-87A2-759E36C9345F

P577

Q34330678-DEE3CB9A-2B3B-4FAB-B230-209A8F656AFF

P6179

Q34330678-ABAF438C-2115-48C3-A005-5F32925A2713

P698

Q34330678-FA27DCD0-FC9D-483B-816E-26F5B11F28A9

P921

Q34330678-0BFAEFFD-39C3-49B4-BFCB-6D9D6D884843

P356

S00406-013-0399-Y

P1433

European Archives of Psychiatry and Clinical Neuroscience

P1476

Glutamate modulators as potent ...... hrenia and affective disorders

@en

P2093

Berend Malchow

http://www.w3.org/2001/XMLSchema#string

P2860

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists

P2888

s00406-013-0399-y

P304

367-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00406-013-0399-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

263

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029659627

http://www.w3.org/2001/XMLSchema#string

P698

23455590

http://www.w3.org/2001/XMLSchema#string

P921